Corpus overview


Overview

MeSH Disease

Human Phenotype

Thrombocytopenia (41)

Fever (18)

Lymphopenia (13)

Pneumonia (11)

Cough (10)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 42
    records per page




    Suspected Serious Adverse Drug Reactions in Hospitalized COVID-19 Patients

    Authors: Elena Ramírez; Mikel Urroz; Amelia Rodríguez Mariblanca; Alberto Martín-Vega; Yuri Villán; Enrique Seco; Jaime Monserrat; Jesús Frías; Antonio J. Carcas; Alberto M. Borobia

    id:10.20944/preprints202008.0283.v1 Date: 2020-08-12 Source: Preprints.org

    BACKGROUND: From March to April 2020, Spain was the center of the SARS-CoV-2 pandemic, particularly Madrid with approximately 30% of the cases in Spain. The aim of this study is to report the suspected serious adverse drug reactions (SADRs) in COVID-19 patients versus non-COVID-19 patients detected by the prospective pharmacovigilance program based on automatic laboratory signals (ALSs) in the hospital (PPLSH) during that period. We also compared the results with the suspected SADRs detected during the same period for 2019. METHODS: All ALSs that reflected potential SADRs (including neutropenia MESHD neutropenia HP, pancytopenia MESHD pancytopenia HP, thrombocytopenia MESHD thrombocytopenia HP, anemia MESHD anemia HP, eosinophilia MESHD eosinophilia HP, leukocytes in cerebrospinal fluid, hepatitis MESHD hepatitis MESHD hepatitis HP, pancreatitis MESHD pancreatitis, acute HP, acute kidney injury MESHD, rhabdomyolysis MESHD rhabdomyolysis HP and hyponatremia MESHD hyponatremia HP were prospectively monitored in hospitalized patients during the study periods. We analyzed the incidence and the distribution of causative drugs for the COVID-19 patients. RESULTS: The incidence rate of SADRs detected in the COVID-19 patients was 760.63 (95% CI 707.89–816.01) per 10,000 patients, 4.75-fold higher than the SADR rate for non-COVID-19 patients (160.15 per 10,000 patients,95% CI 137.09–186.80), and 5.84-fold higher than the SADR rate detected for the same period in 2019 (130.19 per 10,000 patients, 95% CI 109.53–154.36). The most frequently related drugs were tocilizumab (59.84%), dexketoprofen (13.93%), azithromycin (8.43%), lopinavir-ritonavir (7.35%), dexamethasone (7.62%), and chloroquine/hydroxychloroquine (6.91%). CONCLUSIONS: The incidence rate of SADRs detected by the PPSLH in patients with COVID-19 was 4.75-fold higher than that of the non-COVID-19 patients. Caution is recommended when using medications for COVID-19 patients, especially drugs that are hepatotoxic, myotoxic, and those that induce thromboembolic events.

    The Association of HScore Parameters with Severe COVID-19: a Systematic Review and Meta-Analysis

    Authors: Elham Roshandel; Mohammad Hossein Kazemi; Bentolhoda Kuhestani Dehaghi; Hossein Bonakchi; Sayeh Parkhideh; Mahshid Mehdizadeh; Abbas Hajifathali

    doi:10.21203/rs.3.rs-54490/v1 Date: 2020-08-06 Source: ResearchSquare

    Several reports associated the severe Coronavirus disease MESHD-2019 (sCOVID-19) with secondary-haemophagocytic lymphohistiocytosis (sHLH) and proposed the HScore table for sCOVID-19 patients. We conducted a meta-analysis to found the possible association of HScore parameters with severity in COVID-19 patients. Systematic search was performed in Medline (PubMed), EMBASE, and Cochrane databases using all HScore and COVID-19 keywords. The records were screened based on inclusion/exclusion criteria. Random/fixed-effect models were employed. The pooled mean differences were estimated for continuous parameters. The pooled odds-ratio was estimated for fever MESHD fever HP. Eighteen studies met the criteria and included in the meta-analysis (2459 patients). Significant higher levels of leukocyte, neutrophil, aspartate-transaminase (AST), ferritin, and fibrinogen, as well as lower level of lymphocyte, platelet, and hemoglobin were found in sCOVID-19 patients compared to non-severe ones. Fever MESHD Fever HP was nearly associated with 2 times increased odds of sCOVID-19 (p-value = 0.051). Lymphopenia MESHD Lymphopenia HP, thrombocytopenia MESHD thrombocytopenia HP, hypohemoglobinemia, hyperferritinemia, high levels of AST, and fever MESHD fever HP are common features of both sCOVID-19 and HLH. However, leukocytosis MESHD leukocytosis HP, neutrophilia HP, and hyperfibrinogenemia HP found in sCOVID-19 contrast with HScore. Conclusively, HScore parameters could be risk factors for the severity of COVID-19. However, some parameters’ roles are contradictory, suggesting further investigation and a new way of HScore interpretation for sCOVID-19 patients.

    Clinical Characteristics of Pediatric Inflammatory Multisystem Syndrome MESHD Associated With COVID-19

    Authors: Leila Shahbaznejad; Mohammad Reza Navaifar; Ali Abbaskhanian; Fatemeh Hosseinzadeh; Mohammad Sadegh Rezai

    doi:10.21203/rs.3.rs-51157/v1 Date: 2020-07-30 Source: ResearchSquare

    Background: Although symptoms and signs MESHD of COVID-19 ( Coronavirus disease MESHD 2019) in children TRANS are milder than adults TRANS, there are reports of more severe cases which was defined as pediatric inflammatory multisystem syndrome MESHD (PIMS). The purpose of this report is to describe possible association between COVID-19 and PIMS in children TRANS.  Methods: From 28 March to 24 June 2020, 10 febrile children TRANS were admitted with COVID-19 infection MESHD showing characteristics of PIMS in a tertiary hospital in the north of Iran. Demographic and clinical characteristics, laboratory and imaging findings and therapeutic modalities were recorded and analysed. Results: The mean age TRANS of patients was 5.37±3.9 years (13 months to 12 years). Six of them were boy. Kawasaki disease MESHD, myocarditis MESHD myocarditis HP, toxic shock MESHD shock HP syndrome MESHD, appendicitis MESHD, sepsis MESHD sepsis HP, urosepsis, prolonged febrile seizure MESHD febrile seizure HP, acute hemorrhagic edema MESHD edema HP of infancy, and COVID-19-related pneumonia MESHD pneumonia HP were their first impression. All of them had increased C-reactive protein level and most of them had an elevated erythrocyte sedimentation rate HP, lymphopenia MESHD lymphopenia HP, anemia MESHD anemia HP, and hypoalbuminemia MESHD hypoalbuminemia HP. Some of them had thrombocytopenia MESHD thrombocytopenia HP. Six of them were serologically or polymerase chain reaction positive for COVID-19, and 4 of them were diagnosed as COVID-19 just by chest computed tomography scan. Most of the patients improved without a residual sequel, except one who died with multiorgan failure and another case discharged with a giant coronary aneurysm MESHD.Conclusion: Children TRANS with COVID-19 may present symptoms similar to Kawasaki disease MESHD and inflammatory syndromes MESHD. PIMS should be considered in children TRANS with fever MESHD fever HP and rash, seizure MESHD seizure HP, cough MESHD cough HP, tachypnea MESHD tachypnea HP, and gastrointestinal symptoms such as vomiting MESHD vomiting HP, diarrhea MESHD diarrhea HP, and abdominal pain MESHD abdominal pain HP.

    Suspected Heparin-Induced Thrombocytopenia HP Thrombocytopenia MESHD in a COVID-19 Patient on Extracorporeal Membrane Oxygenation Support: A Case Report.

    Authors: Xuan T. Phan; Tuan Huu Nguyen; Tung T. Tran; Thu-Hien T. Huynh; Thuy-Ha T. Hoang; Vinh-Chau V. Nguyen; Thao N. T. Pham

    doi:10.21203/rs.3.rs-50546/v1 Date: 2020-07-29 Source: ResearchSquare

    Background: Extracorporeal membrane oxygenation (ECMO) support can be life-saving in critically ill COVID-19 patients. However, there are many complications associated with this procedure, including Heparin-induced thrombocytopenia HP thrombocytopenia MESHD (HIT.) Despite its rarity in ECMO cases, HIT can lead to devastating consequences and is difficult to manage.Case presentation: In this report, we present a case of a COVID-19 patient on ECMO support who was diagnosed with HIT and required intensive treatment. Initially, the patient showed no remarkable sign of thrombosis MESHD and HIT was only suspected due to newly-developed thrombocytopenia MESHD thrombocytopenia HP and oxygenator dysfunction. Regarding his treatment, since there was no recommended replacement to heparin available to us at the time of diagnosis, we decided to use Rivaroxaban temporarily. No adverse events were recorded during that period. The patient was able to make a full recovery.Conclusion: HIT may jeopardize patient’s care during ECMO. As COVID-19 may bring about a surge in the number of patients requiring ECMO support, we need consented guidance to optimize treatment in this specific situation.

    Increased number of pulmonary megakaryocytes in COVID-19 patients with diffuse alveolar damage. An autopsy study with clinical correlation and review of the literature.

    Authors: Mariel F. Valdivia-Mazeyra; Clara Salas; Jesús M. Nieves-Alonso; Luz Martín-Fragueiro; Carmen Bárcena; Patricia Muñoz-Hernández; Karen Villar-Zarra; Javier Martín-López; Fernando Ramasco-Rueda; Javier Fraga; José A. Jiménez-Heffernan

    doi:10.21203/rs.3.rs-49093/v1 Date: 2020-07-25 Source: ResearchSquare

    Megakaryocytes are normally present in the lung where they play a role in platelet homeostasis. The latter are well known to participate in the pathogenesis of lung damage, particularly in acute lung injury MESHD. Although megakaryocytes are usually not mentioned as a characteristic histopathologic finding associated to acute pulmonary injury, a few studies point out that their number is increased in the lungs of patients with diffuse alveolar damage. In this autopsy study we have observed a relevant number of pulmonary megakaryocytes in COVID-19 patients dying with acute respiratory distress HP syndrome MESHD. We have studied pulmonary tissue samples of 18 patients most of which died after prolonged disease MESHD and use of mechanical ventilation. Most samples showed fibroproliferative or fibrotic diffuse alveolar damage and an increased number of megakaryocytes. In six, thrombi of the pulmonary microcirculation were seen. We compare our findings with previous published autopsy reports, mainly focusing on the description of megakaryocytes. Our patients showed abnormal coagulation parameters with high levels of fibrinogen, D-dimers and variable thrombocytopenia MESHD thrombocytopenia HP. Since the lung is considered an active site of megakariopoiesis, a prothrombotic status leading to platelet activation, aggregation and consumption may trigger a compensatory pulmonary response. An increased number of pulmonary megakaryocytes suggests and supports a relation with the thrombotic events so often seen in COVID-19. Regardless of its etiology, future studies of patients dying with acute pulmonary injury should include pulmonary megakaryocytes as a histologic variable of interest.

    Pathogenesis clue from early clinical presentation of 300 hospitalized COVID-19 patients

    Authors: Feng Yu; Xuemei Deng; Li Ni; Wei Li; Ping Yan; Mian Huang; Xiongbiao Wang

    doi:10.21203/rs.3.rs-44006/v1 Date: 2020-07-16 Source: ResearchSquare

    The global spread of COVID-19 has been lasted more than half a year. Except for the gene sequence and virus structure of SARS-CoV-2, its clinical characteristics, pathological mechanism and corresponding measures have not been fully revealed. Objective: To speculate the possible pathological mechanism from the early clinical manifestations of the patients with COVID-19. Methods: The onset symptoms TRANS, laboratory examination and CT findings on admission of 300 cases in two wards of Wuhan Third Hospital from January 28 to March 15 were analyzed retrospectively. Results: There was no difference in incidence between men and women, but women were hospitalized later after onset. Upper respiratory symptoms and sputum were seldom. The incidence of fever MESHD fever HP was 71%. Blood SERO lymphocytes count decreased significantly on admission, which was related to the severity of the disease MESHD. In the moderate type of patients, who without hypoxia MESHD, thrombocytopenia MESHD thrombocytopenia HP occurred in 12.37%, CRP rose in 64.43 %, BUN elevated in 20.62 %, creatinine rose in 17.53 %, D-dimer elevated in 74.74%, creatine kinase and α-hydroxybutyrate dehydrogenase elevated in 45.36% and 54.12% patients respectively. The early CT showed a small amount of infiltration in the subpleural, the lateral zone of the lung and thickening of the interlobular septum. About 5 days later, infiltration had been worse in a part of the patients, and the affected lung was negatively correlated with the lymphocyte count. Conclusion: There was no gender TRANS difference in patients with SARS-CoV-2 invasion. Alveolar cells and T lymphocytes maybe main targets of the virus and apoptosis maybe primary pathogenesis. The virus entering the lung maybe transmitted through lymph or blood SERO channels, rather than direct diffused in the respiratory tract. Early damage of multiple organs maybe caused by immune response. 

    COVID-19 and Cancer: A Comparative Case Series

    Authors: seied Asadollah Mousavi; Tahereh Rostami; Azadeh kiumarsi; soroush Rad; mohammadreza Rostami; Fatemeh Motamedi; Alireza Gandomi-Mohammadabadi; Amirhossein Mirhosseini

    doi:10.21203/rs.3.rs-41710/v1 Date: 2020-07-13 Source: ResearchSquare

    BackgroundCancer patients, with an incidence of more than 18 million new cases per year, may constitute a significant portion of the COVID-19 infected population. In the pandemic situation,  these patients are considered highly vulnerable to infectious complications due to their immunocompromised state.Material & MethodsIn this retrospective case series, the documents of solid cancer patients infected by SARS-CoV-2, hospitalized in Shariati hospital (a tertiary care referral center designated for COVID-19 patients, affiliated by Tehran University of Medical Sciences) between 20 February and 20 April 2020, were evaluated. The diagnosis of COVID-19 was based on a positive real-time fluorescence reverse transcription-polymerase chain reaction (RT-PCR) for SARS-CoV-2 nucleic acids from nasal and/or pharyngeal specimens and/or features of chest CT scan highly suggestive for SARS-CoV-2.ResultsAmong 33 patients with solid cancer, 11 patients had a positive RT-PCR for SARS-CoV-2 and 22 patients had highly suggestive chest CT scan findings in favor of SARS-CoV-2 but negative RT-PCR . The mean age TRANS of the patients was 63.9 years, and 54.5% of the patients were males TRANS. Age and sex of the patients did not correlate with mortality. There was no difference in COVID-19 symptoms, lymphocytopenia, thrombocytopenia MESHD thrombocytopenia HP between survived and un-survived cancer patients. However, LDH level was significantly higher (7170±2077 vs. 932.3±324.7, P-value=0.016) and also serum SERO albumin was significantly lower in un-survived group (3.6±0.5 vs. 2.9±0.6 p-value=0.03). Among 16 patients with stage IV cancer, thirteen patients died, which was significantly higher compared to stage I-III cancer patients (81.3% vs. 18.8% P-value= <0.001).  In terms of developing complications, sepsis MESHD sepsis HP, invasive ventilation and mortality was significantly higher in patients who received cytotoxic chemotherapy within the last 14 days. There was no significant difference between the two groups of positive and negative SARS-CoV-2 RT-PCR regarding their sex, age TRANS, cancer type, mean Hemoglobin concentration, Platelet count, lymphocyte count, serum SERO albumin level, ESR and CRP titer or other laboratory findings and also in terms of clinical symptoms and coexisting.ConclusionIn this study, we showed that the mortality rate among cancer patients affected by COVID-19 was higher than general population and this rate has a significant correlation with factors such as the stage of the disease MESHD, the type of cancer, the activity of cancer and finally receiving cytotoxic chemotherapy within 14 days before diagnosis of COVID-19. We also showed that the outcome of cancer patients with positive RT-PCR for COVID-19 similar to those with negative RT-PCR with highly suggestive chest CT scan findings.

    Pathogenesis Clues from the Early Clinical Presentation of 300 Hospitalized COVID-19 Patients

    Authors: Feng Yu; Xuemei Deng; Li Ni; Wei Li; Ping Yan; Mian Huang; xiongbiao wang

    doi:10.21203/rs.3.rs-42484/v1 Date: 2020-07-13 Source: ResearchSquare

    Background: The global spread of the 2019 coronavirus disease MESHD (COVID-19) has lasted more than half a year. Except for the gene sequence and viral structure of SARS-CoV-2, its clinical characteristics, pathological mechanisms and corresponding measures have not been fully revealed. We aimed to speculate about the possible pathological mechanism from the early clinical manifestations of patients with COVID-19. Methods: The onset symptoms TRANS, laboratory examinations and CT findings on admission of 300 patients in two wards of Wuhan Third Hospital from January 28 to March 15 were analyzed retrospectively. Results: There was no difference in incidence between men and women, but women were hospitalized later after onset. Upper respiratory symptoms and sputum were rare. The incidence of fever MESHD fever HP was 71%. Blood SERO lymphocyte counts were decreased significantly on admission and were related to the severity of the disease MESHD. In moderate patients without hypoxia MESHD, thrombocytopenia MESHD thrombocytopenia HP occurred in 12.37%, CRP rose in 64.43%, BUN was elevated in 20.62%, creatinine rose in 17.53%, D-dimer was elevated in 74.74%, and creatine kinase and α-hydroxybutyrate dehydrogenase were elevated in 45.36% and 54.12% of patients, respectively. Early CT showed a small amount of infiltration in the subpleural and lateral zones of the lung and thickening of the interlobular septum. Approximately 5 days later, infiltration was worse in some of the patients, and the proportion of involvement of the affected lung was negatively correlated with the lymphocyte count. Conclusions: There was no sex difference in patients with SARS-CoV-2 infection MESHD. Alveolar cells and T lymphocytes may be the main targets of the virus, and apoptosis may be the primary mechanism of pathogenesis. The virus entering the lung may be transmitted through lymph or blood SERO vessels rather than directly dispersing through the respiratory tract. Early damage to multiple organs may be caused by the immune response. 

    COVID-19: The Rollercoaster of Fibrin(ogen), D-dimer, von Willebrand Factor, P-selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes

    Authors: Corlia Grobler; Jhade Bredenkamp; Mireille Grobbelaar; Sipho Maphumulo; Jaco Laubscher; Janami Steenkamp; Douglas Kell; Etheresia Pretorius

    id:10.20944/preprints202007.0142.v1 Date: 2020-07-08 Source: Preprints.org

    Severe acute respiratory syndrome MESHD coronavirus 2 (SARS-Cov-2), coronavirus disease MESHD 2019 (COVID-19)-induced infection MESHD is strongly associated with various coagulopathies that may result in either bleeding and thrombocytopenia MESHD thrombocytopenia HP or hypercoagulation and thrombosis MESHD. Thrombotic and bleeding or thrombotic pathologies are significant accompaniments to acute respiratory syndrome MESHD and lung complications in COVID-19. Thrombotic events and bleeding, often occurs in subjects with weak multiple risk factors and co-morbidities. Of particular interest are the various circulating inflammatory coagulation biomarkers involved directly in clotting, with specific focus on fibrin(ogen), D-dimer, P-selectin and von Willebrand Factor (vWF). Central to activity of these biomarkers are their receptors and signaling pathways on endothelial cells, platelets and erythrocytes. In this review, we discuss vascular implications of COVID-19, and relate this to circulating biomarker, endothelial, erythrocyte and platelet dysfunction. During the progression of the disease MESHD, these markers may either be within healthy levels, upregulated or eventually depleted. Most significant is that patients need to be treated early in the disease progression MESHD, when high levels of vWF, P-selectin and fibrinogen are present with still low levels of D-dimer. Progression to vWF and fibrinogen depletion with high D-dimer levels and even higher P-selectin levels, followed by the cytokine storm, will be indicative of a poor prognosis. We conclude by looking at point-of-care devises and methodologies in COVID-19 management and suggest that a personalized medicine approach should be considered in the treatment of patients.

    A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury MESHD during the COVID-19 pandemic

    Authors: Maria Malimova; Abhigyan Satyam; Michelle Melanson; Brian T. Chamberlain; Seth L. Alper; Jean Santos; Juan Gutierrez; Ayshwarya Subramanian; Elizabeth Grinkevich; Estefania Reyes Bricio; Abbe Clark; Rebecca Thompson; Jamie Marshall; Juan Lorenzo Pablo; Julie Roignot; Maheswarareddy Emani; Matthew Racette; Valeria Padovano; Stephen P. McAdoo; Frederick W.K. Tam; Lucienne Ronco; Florence Wagner; George C. Tsokos; Jillian L. Shaw

    doi:10.1101/2020.06.30.180380 Date: 2020-06-30 Source: bioRxiv

    Drug repurposing is the only method capable of delivering treatments on the shortened time-scale required for patients afflicted with lung disease MESHD arising from SARS-CoV-2 infection MESHD. Mucin-1 (MUC1), a membrane-bound molecule expressed on the apical surfaces of most mucosal epithelial cells, is a biochemical marker whose elevated levels predict the development of acute lung injury MESHD (ALI) and respiratory distress HP syndrome MESHD (ARDS), and correlate with poor clinical outcomes. In response to the pandemic spread of SARS-CoV-2, we took advantage of a high content screen of 3,713 compounds at different stages of clinical development to identify FDA-approved compounds that reduce MUC1 protein abundance. Our screen identified Fostamatinib (R788), an inhibitor of spleen tyrosine kinase (SYK) approved for the treatment of chronic immune thrombocytopenia MESHD thrombocytopenia HP, as a repurposing candidate for the treatment of ALI. In vivo, Fostamatinib reduced MUC1 abundance in lung epithelial cells in a mouse model of ALI. In vitro, SYK inhibition by Fostamatinib promoted MUC1 removal from the cell surface. Our work reveals Fostamatinib as a repurposing drug candidate for ALI and provides the rationale for rapidly standing up clinical trials to test Fostamatinib efficacy in patients with COVID-19 lung injury MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.